EUVIMEDEUVIMED entdecken
Crossref

Senkyunolide I alleviates allergic rhinitis by inhibiting JAK1/3-STAT3/6 and JNK signalings

Ting Liu, Tian Wen, Xiaofei Shen, Chunguang Xie, Rong Zhang, Li Tian

International Immunopharmacology · 2025

DOI: 10.1016/j.intimp.2025.115462 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Ting Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu University of Traditional Chinese Medicine, Che…. Hauptthemen laut MEDLINE: Rhinitis, Allergic, Anti-Allergic Agents, Anti-Inflammatory Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Department of Sichuan Province, Natural Science Foundation of Sichuan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Allergic rhinitis (AR) is a common allergic disease with a high incidence rate. Senkyunolide I (SEI), a bioactive ingredient isolated from Ligusticum sinense 'Chuanxiong', exhibits known analgesic and anti-inflammatory effects, yet its anti-AR potential remains unexplored. Here, we aim to investigate the therapeutic efficacy and molecular mechanisms of SEI against AR. METHODS: In IL-4-stimulated human nasal epithelial cells (HNEpCs), the levels of allergic mediators were quantified by RT-qPCR. The anti-AR efficacy of SEI was then validated in ovalbumin (OVA)/Al(OH)3-induced mice. Mechanistic studies combining western blotting, CETSA, and molecular docking identified the molecular mechanisms and targets of SEI. RESULTS: In vitro, SEI effectively reduced IL-4-induced mRNA expression of CCL11, CCL26, IL-33, periostin, VCAM-1, and MUC5AC in HNEpCs. Furthermore, oral administration of SEI significantly alleviated OVA/Al(OH)3-induced AR in mice, which mainly manifested as: (1) reduced serum levels of IL-4, IL-13, OVA-IgE, and IgE; (2) decreased nasal lavage fluid (NALF) levels of IL-4, IL-13, and OVA-IgE; (3) down-regulated mRNA expression of CCL11, CCL26, IL-5, IL-33, periostin, and MUC5AC; and (4) inhibited infiltration of eosinophils and mast cells in the nasal mucosa. Mechanistically, SEI was able to directly interact with JAK1/3 kinases, resulting in the inactivation of JAK1/3-STAT3/6 signaling cascades in IL-4-stimulated HNEpCs and OVA/Al(OH)3-challenged mice. Additionally, SEI was found to inhibit IL-4-induced JNK phosphorylation in vitro and in vivo. CONCLUSION: We confirmed that SEI alleviated AR via inhibiting JAK1/3-STAT3/6 and JNK pathways, raising the possibility that SEI could function as a promising candidate for the therapy of AR or other allergic diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rhinitis, AllergicAnti-Allergic AgentsAnti-Inflammatory AgentsAnimalsHumansSTAT3 Transcription FactorJanus Kinase 1MiceOvalbuminMice, Inbred BALB CNasal MucosaSignal TransductionMaleDisease Models, AnimalCytokinesMAP Kinase Signaling SystemJanus Kinase 3Female

Stichwörter der Autor:innen

Allergic rhinitisIL-4JAK1/3JNKSTAT3/6Senkyunolide I

Substanzen

STAT3 Transcription FactorJanus Kinase 1OvalbuminAnti-Allergic AgentsJAK1 protein, humanCytokinesJanus Kinase 3Anti-Inflammatory Agents

Autor:innen und Institutionen

  • Department of Otolaryngology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China; TCM Prevention and Treatment of Metabolic and Chro…
  • TCM Prevention and Treatment of Metabolic and Chronic Diseases Key Laboratory of Sichuan Province, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu University of Traditional Chinese Medicine, Chen…
  • Jiangsu Province Hospital of Chinese Medicine, Nanjing 210004, China. Electronic address: cheung0213@hotmail.com.
  • Department of Otolaryngology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China. Electronic address: ctcmdan@stu.cdutcm.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Department of Sichuan Province
  • Natural Science Foundation of Sichuan Province

Zitieren

APA

Liu, T., Wen, T., Shen, X., Xie, C., Zhang, R., & Tian, L. (2025). Senkyunolide I alleviates allergic rhinitis by inhibiting JAK1/3-STAT3/6 and JNK signalings. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115462

Vancouver

Liu T, Wen T, Shen X, Xie C, Zhang R, Tian L. Senkyunolide I alleviates allergic rhinitis by inhibiting JAK1/3-STAT3/6 and JNK signalings. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115462

BibTeX
@article{Liu2025,
  author = {Liu, Ting and Wen, Tian and Shen, Xiaofei and Xie, Chunguang and Zhang, Rong and Tian, Li},
  title = {Senkyunolide I alleviates allergic rhinitis by inhibiting JAK1/3-STAT3/6 and JNK signalings},
  journal = {International Immunopharmacology},
  year = {2025},
  doi = {10.1016/j.intimp.2025.115462}
}
Kostenlos starten →